Wednesday, April 28, 2021 7:00 PM EST - 8:00 PM EST
Dr. Barb Melosky
This program was made possible through sponsorship support from Amgen.
ABOUT THE SPEAKER:
Dr. Adrian Sacher is a staff medical oncologist at Princess Margaret Hospital and an assistant professor in the Departments of Medicine & Immunology at the University of Toronto. Dr. Sacher completed his medical degree at the University of Toronto and residency at the Toronto General Hospital and Princess Margaret Cancer Center. He has previously completed a fellowship in thoracic oncology at the Dana-Farber Cancer Institute and holds a master’s degree in clinical trial design, genomics and drug development from Harvard Medical School.
Dr. Sacher’s research focuses on novel immunotherapeutics including immune checkpoint inhibitors, immune agonists, personalized vaccines, epigenetic therapy, direct KRAS inhibitors and adoptive cell therapy. He is primarily interested in understanding the mechanisms of primary and acquired resistance to immunotherapy and developing tissue and blood based biomarkers as well as humanized animal models to better understand the biology of anti-tumor immune responses. He has a particular interest in the immunobiology of KRAS mutant tumors and therapeutic strategies to address oncogene addicted cancers. He has significant previous translational research experience in both tissue genomics and the development of blood-based biomarkers including plasma genotyping.
ABOUT THE CHAIR:
Dr. Barb Melosky is a Clinical Professor of medicine at the University of British Columbia and a medical oncologist in Vancouver at the British Columbia Cancer Agency. Dr. Melosky specializes in the field of thoracic malignancy. She is head of the Lung Tumor Group at BC Cancer.
She sits on the Executive Lung Site Committee for Canadian Clinical Trials Group CTTG. Dr. Melosky chaired the Canadian Lung Cancer Conference for the last 21 years, which is attended by over 500 participants. She organizes and chairs the Lung Cancer Journal Club. She is chair and created the British Columbia Lung Cancer Biobank.
She is published extensively and is considered a national and international expert in thoracic malignancies.
Questions can be directed to email@example.com.